Category - Developments

Developments

vTv Therapeutics reports positive topline results from Phase 2 diabetes trial

vTv Therapeutics (NASDAQ:VTVT) reported positive topline results from its Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients.

June 6, 2019

Developments

La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).

June 6, 2019

Developments

Anavex doses first patient in Phase 2 Rett Syndrome trial

Anavex Life Sciences (NASDAQ:AVXL) dosed the first patient in its Phase 2 trial of ANAVEX2-73 for the treatment of Rett syndrome.

June 6, 2019

Developments

Axovant reports six-month data from Phase 2 Parkinson’s disease trial

Axovant Gene Therapies (NASDAQ:AXGT) reported six-month data from its Phase 2 trial of AXO-Lenti-PD, a gene therapy for Parkinson’s disease (PD). AXO-Lenti-PD uses a single lentiviral vector to deliver three genes...

June 6, 2019

Developments

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...

June 6, 2019

Developments

FDA grants Sierra Oncology fast track designation for momelotinib

Sierra Oncology (NASDAQ:SRRA) received FDA fast track designation for momelotinib for the treatment of myelofibrosis. Momelotinib is designed to improve anemia that frequently occurs in myelofibrosis, or cancer of the...

June 5, 2019

Developments

AnaptysBio presents updated Phase 2a data of etokimab in asthma

AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...

June 5, 2019

Developments

Concert Pharmaceuticals completes enrollment in alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in a trial to compare once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial...

June 5, 2019

Developments

Helius Medical adds 3 PoNS clinics in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) added three new clinics authorized to provide PoNS treatment in Canada, extending regional access to its innovative treatment.

June 5, 2019

Developments

Aimmune reports new Phase 3 data for peanut allergy immunotherapeutic

Aimmune Therapeutics (NASDAQ:AIMT) reported new data from a Phase 3 study of AR101, which delivers a daily dose of peanut protein, as a treatment to reduce the frequency and severity of allergic reactions to peanuts...

June 4, 2019

Category - Developments

vTv Therapeutics reports positive topline results from Phase 2 diabetes trial

La Jolla Pharma reports interim results from Phase 2 hemochromatosis trial

Anavex doses first patient in Phase 2 Rett Syndrome trial

Axovant reports six-month data from Phase 2 Parkinson’s disease trial

ContraVir Pharma sets stage for CRV431 development in NASH with positive results in second model of liver fibrosis

FDA grants Sierra Oncology fast track designation for momelotinib

AnaptysBio presents updated Phase 2a data of etokimab in asthma

Concert Pharmaceuticals completes enrollment in alopecia areata trial

Helius Medical adds 3 PoNS clinics in Canada

Aimmune reports new Phase 3 data for peanut allergy immunotherapeutic

General

More